Page last updated: 2024-11-05

thalidomide and Demyelinating Diseases

thalidomide has been researched along with Demyelinating Diseases in 3 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Demyelinating Diseases: Diseases characterized by loss or dysfunction of myelin in the central or peripheral nervous system.

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19901 (33.33)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Larsen, LH1
Lund, T1
Vilholm, OJ1
Plesner, T1
Kuwabara, S1
Thomas, PK1

Reviews

2 reviews available for thalidomide and Demyelinating Diseases

ArticleYear
[New treatment strategy for Crow-Fukase (POEMS) syndrome].
    Rinsho shinkeigaku = Clinical neurology, 2010, Volume: 50, Issue:11

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Boronic Acids; Bortezomib;

2010
The morphological basis for alterations in nerve conduction in peripheral neuropathy.
    Proceedings of the Royal Society of Medicine, 1971, Volume: 64, Issue:3

    Topics: Amyloidosis; Animals; Axons; Beriberi; Cresols; Demyelinating Diseases; Diabetic Neuropathies; Diffu

1971

Other Studies

1 other study available for thalidomide and Demyelinating Diseases

ArticleYear
Anti-myelin associated glycoprotein neuropathy responding to lenalidomide.
    Leukemia research, 2011, Volume: 35, Issue:11

    Topics: Aged; Antineoplastic Agents; Demyelinating Diseases; Humans; Immunoglobulin M; Lenalidomide; Male; M

2011